Aaron Wealth Advisors LLC Increases Stock Position in AbbVie Inc. $ABBV

Aaron Wealth Advisors LLC lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 18.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 25,340 shares of the company’s stock after acquiring an additional 3,983 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in AbbVie were worth $5,790,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of ABBV. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie in the 2nd quarter worth approximately $26,000. Chelsea Counsel Co. purchased a new stake in shares of AbbVie in the 3rd quarter worth approximately $26,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie in the 4th quarter worth approximately $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie in the 3rd quarter worth approximately $31,000. Finally, Caitlin John LLC purchased a new stake in shares of AbbVie in the 3rd quarter worth approximately $33,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts and outlets highlight AbbVie’s valuation and income appeal — calls that the shares look like a strong value play for long‑term investors given yield and discounted multiples. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Positive Sentiment: Seeking Alpha notes that while 2026 sets a high earnings bar, AbbVie’s shares remain attractive on valuation — a constructive view that can support the stock over time if guidance is met. AbbVie: A High 2026 Earnings Bar, But Shares Are Attractive On Valuation
• Positive Sentiment: Comparisons with peers emphasize AbbVie’s attractive dividend profile versus Pfizer, supporting income‑focused demand for the stock. High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout
• Positive Sentiment: Analysts are watching Skyrizi and Rinvoq as the key growth drivers for Q1 immunology sales and market‑share recovery as Humira wanes — successful execution here would materially reinforce revenue trajectory. How Will Skyrizi and Rinvoq Shape AbbVie’s Q1 Immunology Sales?
• Neutral Sentiment: Sector news: two more drug firms are joining the TrumpRx pricing initiative — a broader pricing‑pressure story that could matter to big pharma if it expands, though the immediate impact on AbbVie is uncertain. Two more drug companies to officially launch on TrumpRx
• Neutral Sentiment: Miscellaneous industry piece (Regeneron/Kiniksa Arcalyst orphan‑drug coverage) is not AbbVie‑specific but contributes to wider sector investor interest in niche drug opportunities. Stock Of The Day In Buy Zone, Leads Industry Despite Supersmall Market
• Negative Sentiment: AbbVie lowered its Q1 and full‑year 2026 earnings outlook after taking a $744M R&D charge — a direct negative to near‑term earnings expectations and a primary reason for the share weakness. AbbVie lowers Q1 and FY 2026 earnings outlook following $744M R&D charge
• Negative Sentiment: Market coverage notes the stock has underperformed peers and declined despite broader market gains — reinforcing short‑term selling pressure and investor caution. AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
• Negative Sentiment: Additional note on underperformance vs. competitors from MarketWatch — another datapoint traders use to justify reduced weight in the stock near term. AbbVie Inc. stock underperforms Monday when compared to competitors

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Evercore lowered their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. Piper Sandler increased their target price on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. UBS Group decreased their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. Morgan Stanley increased their target price on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Finally, Guggenheim reissued a “buy” rating on shares of AbbVie in a research report on Thursday, March 12th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.25% of the company’s stock.

AbbVie Stock Down 1.1%

NYSE:ABBV opened at $206.62 on Tuesday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The firm has a 50 day moving average of $221.30 and a 200 day moving average of $224.39. The stock has a market capitalization of $365.35 billion, a price-to-earnings ratio of 87.55, a PEG ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.